Europe
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
Adding to its list of achievements, on Tuesday the Swiss biotech announced it is acquiring Comet Therapeutics.
The hot days of summer are nearing a close, but these life science companies aren’t cooling off their fundraising efforts. Here’s a brief overview of who’s heating up their coffers this week.
As CEO, Stolpe has presided over some highs with the launch of JAK1 inhibitor Jyseleca (filgotinib) in Europe, as well as the devaluation of the company’s share price by 70%.
Shares of Bone Therapeutics are down more than 34% on the Euronext stock exchange after the company announced its Phase III osteoarthritis study failed to meet primary and critical secondary endpoints.
At the six-month mark, 68% of participants reported at least one persistent symptom, which fell to 49% after one year.
Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
Scientists from Oxford University may have found the key to treating endometriosis, a disease that affects around 176 million women worldwide.
Funds will be used to advance the clinical development of Cardior’s lead program, CDR132L, an oligonucleotide-based ncRNA inhibitor targeting micro-RNA-132.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
PRESS RELEASES